Group 1 - Arcutis Biotherapeutics reported a quarterly loss of $0.20 per share, which was better than the Zacks Consensus Estimate of a loss of $0.21, and an improvement from a loss of $0.32 per share a year ago, resulting in an earnings surprise of 4.76% [1] - The company achieved revenues of $65.85 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26%, and showing a year-over-year increase from $49.57 million [2] - Over the last four quarters, Arcutis Biotherapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2 - The stock has increased approximately 10.6% since the beginning of the year, contrasting with a decline of 3.9% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $72.93 million, and for the current fiscal year, it is -$0.55 on revenues of $307.74 million [7] - The Medical - Biomedical and Genetics industry, to which Arcutis Biotherapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Bioventus reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and showing an increase from $0.07 per share a year ago, indicating a positive earnings surprise of 33.33% [1] Financial Performance - The company achieved revenues of $123.88 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.72%, although this represents a decline from $129.46 million in the same quarter last year [2] - Over the last four quarters, Bioventus has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - Bioventus shares have declined approximately 33.1% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $148.6 million, and for the current fiscal year, it is $0.66 on revenues of $565.01 million [7] - The estimate revisions trend for Bioventus is currently favorable, leading to a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Bioventus belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8]

Core Insights - UL Solutions Inc. reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, and showing an increase from $0.28 per share a year ago, resulting in an earnings surprise of 15.63% [1] - The company achieved revenues of $705 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.16% and up from $670 million year-over-year [2] - UL Solutions Inc. shares have increased approximately 20.2% since the beginning of the year, contrasting with a decline of 3.9% in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.47, with projected revenues of $769.66 million, and for the current fiscal year, the EPS estimate is $1.70 on revenues of $3.02 billion [7] - The estimate revisions trend for UL Solutions Inc. is mixed, leading to a Zacks Rank of 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Business - Services industry, to which UL Solutions Inc. belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, ABM Industries, is expected to report quarterly earnings of $0.88 per share, reflecting a year-over-year change of +1.2%, with revenues anticipated to be $2.08 billion, up 2.8% from the previous year [9]

Core Viewpoint - Cipher Mining Inc. reported a quarterly loss of $0.11 per share, aligning with the Zacks Consensus Estimate, compared to earnings of $0.13 per share a year ago [1] - The company has shown mixed performance in terms of revenue and earnings estimates over the past quarters [2][6] Financial Performance - Cipher Mining's revenues for the quarter ended March 2025 were $48.96 million, missing the Zacks Consensus Estimate by 2.48%, but showing an increase from $48.14 million year-over-year [2] - The company has surpassed consensus revenue estimates only once in the last four quarters [2] Stock Performance - Cipher Mining shares have declined approximately 35.8% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.13 on revenues of $51.68 million, and for the current fiscal year, it is -$0.39 on revenues of $255.36 million [7] - The trend of estimate revisions for Cipher Mining is mixed, which may change following the recent earnings report [6] Industry Context - The Technology Services industry, to which Cipher Mining belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - SOPHiA GENETICS reported a quarterly loss of $0.26 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.21, representing an earnings surprise of -23.81% [1] - The company posted revenues of $17.78 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 7.30% and showing an increase from $15.78 million in the same quarter last year [2] - Over the last four quarters, SOPHiA GENETICS has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Market Outlook - SOPHiA GENETICS shares have increased by approximately 2.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.20 on revenues of $17.85 million, and for the current fiscal year, it is -$0.80 on revenues of $74.18 million [7] Industry Context - The Medical Info Systems industry, to which SOPHiA GENETICS belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for SOPHiA GENETICS is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Core Insights - Esperion Therapeutics reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.18, and a decline from earnings of $0.34 per share a year ago, indicating an earnings surprise of -16.67% [1] - The company generated revenues of $65 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 12.58%, but down from $137.74 million year-over-year [2] - Esperion's shares have declined approximately 52.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] Earnings Outlook - The future performance of Esperion's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [4][5] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $64.91 million, and for the current fiscal year, it is -$0.09 on revenues of $338.51 million [7] Industry Context - The Medical - Drugs industry, to which Esperion belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Metagenomi, is expected to report a quarterly loss of $0.62 per share, reflecting a year-over-year change of +47.9%, with revenues anticipated to be $8.75 million, down 21.6% from the previous year [9]

Core Viewpoint - Crescent Energy (CRGY) reported quarterly earnings of $0.56 per share, exceeding the Zacks Consensus Estimate of $0.47 per share, and showing an increase from $0.46 per share a year ago, representing an earnings surprise of 19.15% [1][2] Financial Performance - The company posted revenues of $950.17 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.40%, and up from $657.47 million year-over-year [2] - Over the last four quarters, Crescent Energy has exceeded consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Crescent Energy shares have declined approximately 41% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The company's earnings outlook is uncertain, with current consensus EPS estimates at $0.26 for the upcoming quarter and $1.66 for the current fiscal year, with revenues expected to be $898.17 million and $3.7 billion respectively [7] Industry Context - The Alternative Energy - Other industry, to which Crescent Energy belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Crescent Energy's stock performance [5]

Core Viewpoint - Hims & Hers Health, Inc. reported strong quarterly earnings, exceeding expectations and showing significant year-over-year growth in both earnings and revenues [1][2]. Financial Performance - The company reported earnings of $0.20 per share, surpassing the Zacks Consensus Estimate of $0.12 per share, and up from $0.05 per share a year ago, representing an earnings surprise of 66.67% [1]. - Revenues for the quarter ended March 2025 were $586.01 million, exceeding the Zacks Consensus Estimate by 8.91%, and significantly higher than the $278.17 million reported in the same quarter last year [2]. Stock Performance - Hims & Hers Health shares have increased approximately 68.8% since the beginning of the year, contrasting with a decline of 3.3% in the S&P 500 [3]. - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $562.21 million, and for the current fiscal year, it is $0.64 on revenues of $2.33 billion [7]. - The industry outlook is favorable, with the Medical Info Systems sector ranking in the top 28% of Zacks industries, suggesting strong potential for stock performance [8].

Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this medical device maker would post a loss of $0.16 per share when it actually produced a loss of $0.11, delivering a surprise of 31.25%.Over the last four quarters, the company has sur ...

Core Viewpoint - Verisk (VRSK) is set to release its Q1 fiscal 2025 results on May 7, with expectations of revenue growth and earnings increase compared to the previous year [1][2][4]. Revenue Expectations - The Zacks Consensus Estimate for Verisk's revenues is $745 million, reflecting a 6.5% increase from the same quarter last year [2]. - Revenue estimates from the United States are projected at $612.4 million, indicating a year-over-year growth of 5.4% [3]. - Expected revenues from the U.K. are $55.7 million, showing a 7.3% increase from the prior year [3]. - Revenues from other countries are estimated to rise by 13.5% to $80.6 million [3]. Earnings Expectations - The consensus estimate for earnings per share is $1.67, suggesting a 2.5% growth from the previous year's figure [4]. - Strong margin expansion is anticipated to contribute positively to the bottom line [4]. Earnings Prediction Model - The current model indicates that Verisk may not achieve an earnings beat this quarter, with an Earnings ESP of -2.34% and a Zacks Rank of 4 (Sell) [5].